Bulk Active Ingredients from Pfizer CentreSource - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bulk Active Ingredients from Pfizer CentreSource


Pfizer CentreSource (PCS) has an established reputation for providing high quality Bulk Active Ingredients to the global fine chemicals marketplace. Our broad range of corticosteroids and hormonal steroids is used in a wide variety of sterile-manufacturing-packaging indications. Pfizer is a leading supplier of fine chemicals, steroid APIs, and steroid intermediates. Pfizer’s strength among steroid API suppliers is derived from our backward-integrated production platform based on soy sterol bioconversion and innovative chemical synthesis.

PCS corticosteroid offerings include dexamethasone, hydrocortisone, hydrocortisone acetate, prednisone, and spironolactone.

Hormonal Steroid products from PCS include: progesterone, megestrol acetate, testosterone, testosterone cypionate, and testosterone propionate.

PCS also supplies two grades of neomycin sulfate antibiotic, including Neomycin Sulfate Powder USP/EP and Neomycin Sulfate Micronized USP/EP.

For advanced intermediates, Pfizer’s unique GMP compliant process utilizes soybean-derived sterols and proprietary fermentation processes to create a very broad intermediate platform. This is done at a large scale, a far more efficient process than operations used by competing steroid manufacturers.

Pfizer CentreSource (PCS)
Website:  www.pfizercentresource.com
Email: Kenneth.F.Ball@pfizer.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here